uploads/2018/02/virus-1812092_1280.jpg

Analyst Ratings for Vanda Pharmaceuticals and Peers in February

By

Updated

Company overview

Vanda Pharmaceuticals (VNDA) is a biopharmaceutical company with a focus on developing and commercializing innovative therapies. The company’s key products on the market are Hetlioz and Fanapt.

Article continues below advertisement

Business strategy

Vanda Pharmaceuticals has adopted a five-pronged business strategy with a goal of becoming a leading global biopharmaceutical company. That involves maximizing the commercial success of Hetlioz and Fanapt, entering into strategic partnerships to supplement its own capabilities, pursuing clinical development and regulatory approval of products, focusing on developing differentiated products, and expanding its product portfolio through product acquisitions.

Analysts’ ratings

Of the six analysts covering Vanda Pharmaceuticals in February 2018, two of them have given the stock a “strong buy” rating, and three have given it a “buy.” Only one analyst has given the stock a “sell.” The mean rating for the stock is 2.0 with a target price of $20.50.

Peer ratings

Of the 12 analysts covering Alkermes (ALKS) in February 2018, five of them have given the stock a “buy” or higher rating, and seven have given it a “hold.” The mean rating for the stock is 2.5 with a target price of $61.58.

Of the 22 analysts covering Merck & Co. (MRK) in February 2018, 13 of them have given the stock a “buy” or higher rating, and nine have given it a “hold.” The mean rating for the stock is 2.14 with a target price of $66.67.

Of the 23 analysts covering Pfizer (PFE) in February 2018, 12 of them have given the stock a “buy” or higher rating, and nine have given it a “hold.” Two analysts have given it a “strong sell” rating. The mean rating for the stock is 2.57 with a target price of $40.25.

In the next part of this series, we’ll take a look at some of Vanda Pharmaceuticals’ key products.

Advertisement

More From Market Realist